Historical Valuation
CareDx Inc (CDNA) is now in the Fair zone, suggesting that its current forward PS ratio of 2.39 is considered Fairly compared with the five-year average of 32.72. The fair price of CareDx Inc (CDNA) is between 12.20 to 59.26 according to relative valuation methord.
Relative Value
Fair Zone
12.20-59.26
Current Price：17.22
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
CareDx Inc (CDNA) has a current Price-to-Book (P/B) ratio of 3.16. Compared to its 3-year average P/B ratio of 2.55 , the current P/B ratio is approximately 23.84% higher. Relative to its 5-year average P/B ratio of 3.92, the current P/B ratio is about -19.32% higher. CareDx Inc (CDNA) has a Forward Free Cash Flow (FCF) yield of approximately 3.77%. Compared to its 3-year average FCF yield of -1.73%, the current FCF yield is approximately -317.27% lower. Relative to its 5-year average FCF yield of -1.83% , the current FCF yield is about -305.39% lower.
P/B
Median3y
2.55
Median5y
3.92
FCF Yield
Median3y
-1.73
Median5y
-1.83
Competitors Valuation Multiple
AI Analysis for CDNA
The average P/S ratio for CDNA competitors is 5.17, providing a benchmark for relative valuation. CareDx Inc Corp (CDNA.O) exhibits a P/S ratio of 2.39, which is -53.81% above the industry average. Given its robust revenue growth of 20.72%, this premium appears sustainable.
Performance Decomposition
AI Analysis for CDNA
1Y
3Y
5Y
Market capitalization of CDNA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CDNA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CDNA currently overvalued or undervalued?
CareDx Inc (CDNA) is now in the Fair zone, suggesting that its current forward PS ratio of 2.39 is considered Fairly compared with the five-year average of 32.72. The fair price of CareDx Inc (CDNA) is between 12.20 to 59.26 according to relative valuation methord.
What is CareDx Inc (CDNA) fair value?
CDNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CareDx Inc (CDNA) is between 12.20 to 59.26 according to relative valuation methord.
How does CDNA's valuation metrics compare to the industry average?
The average P/S ratio for CDNA's competitors is 5.17, providing a benchmark for relative valuation. CareDx Inc Corp (CDNA) exhibits a P/S ratio of 2.39, which is -53.81% above the industry average. Given its robust revenue growth of 20.72%, this premium appears sustainable.
What is the current P/B ratio for CareDx Inc (CDNA) as of Jan 10 2026?
As of Jan 10 2026, CareDx Inc (CDNA) has a P/B ratio of 3.16. This indicates that the market values CDNA at 3.16 times its book value.
What is the current FCF Yield for CareDx Inc (CDNA) as of Jan 10 2026?
As of Jan 10 2026, CareDx Inc (CDNA) has a FCF Yield of 3.77%. This means that for every dollar of CareDx Inc’s market capitalization, the company generates 3.77 cents in free cash flow.
What is the current Forward P/E ratio for CareDx Inc (CDNA) as of Jan 10 2026?
As of Jan 10 2026, CareDx Inc (CDNA) has a Forward P/E ratio of 21.59. This means the market is willing to pay $21.59 for every dollar of CareDx Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CareDx Inc (CDNA) as of Jan 10 2026?
As of Jan 10 2026, CareDx Inc (CDNA) has a Forward P/S ratio of 2.39. This means the market is valuing CDNA at $2.39 for every dollar of expected revenue over the next 12 months.